Switch theme
Sign up to access all valuation multiples
Jafron Biomedical Co Ltd is a China-based company engaged in the research, development, production, and sales of biomaterials and medical devices. It offers solutions for kidney disease, poisoning, rheumatic immune solution, critical illness and liver disease. The company's products include JFYC-100 pre-punching machine, DX-10 blood purifier, and HA resin hemoperfusion.
1989
n/a
LTM Revenue $383M
LTM EBITDA $166M
$2.3B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Jafron Biomedical has a last 12-month revenue (LTM) of $383M and a last 12-month EBITDA of $166M.
In the most recent fiscal year, Jafron Biomedical achieved revenue of $372M and an EBITDA of $166M.
Jafron Biomedical expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Jafron Biomedical valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $383M | XXX | $372M | XXX | XXX | XXX |
| Gross Profit | $310M | XXX | $300M | XXX | XXX | XXX |
| Gross Margin | 81% | XXX | 81% | XXX | XXX | XXX |
| EBITDA | $166M | XXX | $166M | XXX | XXX | XXX |
| EBITDA Margin | 43% | XXX | 45% | XXX | XXX | XXX |
| EBIT | $150M | XXX | $145M | XXX | XXX | XXX |
| EBIT Margin | 39% | XXX | 39% | XXX | XXX | XXX |
| Net Profit | $119M | XXX | $114M | XXX | XXX | XXX |
| Net Margin | 31% | XXX | 31% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Jafron Biomedical's stock price is CNY 22 (or $3).
Jafron Biomedical has current market cap of CNY 17.4B (or $2.4B), and EV of CNY 16.3B (or $2.3B).
See Jafron Biomedical trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.3B | $2.4B | XXX | XXX | XXX | XXX | $0.15 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Jafron Biomedical has market cap of $2.4B and EV of $2.3B.
Jafron Biomedical's trades at 6.1x EV/Revenue multiple, and 13.6x EV/EBITDA.
Equity research analysts estimate Jafron Biomedical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Jafron Biomedical has a P/E ratio of 20.4x.
See valuation multiples for Jafron Biomedical and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2.4B | XXX | $2.4B | XXX | XXX | XXX |
| EV (current) | $2.3B | XXX | $2.3B | XXX | XXX | XXX |
| EV/Revenue | 5.9x | XXX | 6.1x | XXX | XXX | XXX |
| EV/EBITDA | 13.6x | XXX | 13.6x | XXX | XXX | XXX |
| EV/EBIT | 15.0x | XXX | 15.6x | XXX | XXX | XXX |
| EV/Gross Profit | 7.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | 20.4x | XXX | 21.3x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 19.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialJafron Biomedical's last 12 month revenue growth is 10%
Jafron Biomedical's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Jafron Biomedical's rule of 40 is 44% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Jafron Biomedical's rule of X is 67% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Jafron Biomedical and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 10% | XXX | 10% | XXX | XXX | XXX |
| EBITDA Margin | 43% | XXX | 45% | XXX | XXX | XXX |
| EBITDA Growth | 11% | XXX | 36% | XXX | XXX | XXX |
| Rule of 40 | 44% | XXX | 54% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 67% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 15% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 9% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 42% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Jafron Biomedical acquired XXX companies to date.
Last acquisition by Jafron Biomedical was XXXXXXXX, XXXXX XXXXX XXXXXX . Jafron Biomedical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Jafron Biomedical founded? | Jafron Biomedical was founded in 1989. |
| Where is Jafron Biomedical headquartered? | Jafron Biomedical is headquartered in China. |
| Is Jafron Biomedical publicy listed? | Yes, Jafron Biomedical is a public company listed on SHE. |
| What is the stock symbol of Jafron Biomedical? | Jafron Biomedical trades under 300529 ticker. |
| When did Jafron Biomedical go public? | Jafron Biomedical went public in 2016. |
| Who are competitors of Jafron Biomedical? | Similar companies to Jafron Biomedical include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Jafron Biomedical? | Jafron Biomedical's current market cap is $2.4B |
| What is the current revenue of Jafron Biomedical? | Jafron Biomedical's last 12 months revenue is $383M. |
| What is the current revenue growth of Jafron Biomedical? | Jafron Biomedical revenue growth (NTM/LTM) is 10%. |
| What is the current EV/Revenue multiple of Jafron Biomedical? | Current revenue multiple of Jafron Biomedical is 5.9x. |
| Is Jafron Biomedical profitable? | Yes, Jafron Biomedical is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Jafron Biomedical? | Jafron Biomedical's last 12 months EBITDA is $166M. |
| What is Jafron Biomedical's EBITDA margin? | Jafron Biomedical's last 12 months EBITDA margin is 43%. |
| What is the current EV/EBITDA multiple of Jafron Biomedical? | Current EBITDA multiple of Jafron Biomedical is 13.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
